Agilent

Core revenues grew 4 percent year over year, but the firm missed Wall Street analyst estimates on both the top and bottom lines.

Agilent has agreed to provide customized high-fidelity oligo microarrays for the nucleic acid detection step in SomaLogic's Somascan assay.

A brief recap of Genetics/Genomics news the week of Mar 22, 2019: Novogene, Hologic, Agilent, and Diagenode

UBS granted Agilent a Buy rating and a $92 price target; Fluidigm a Neutral rating and a $14 price target; and Qiagen a Neutral rating with a $42 price target.

The firm's diagnostics and genomics group saw a 13 percent year-over-year revenue increase in the first quarter.

Agilent alleges that Twist CEO Emily Leproust and other employees stole trade secrets from it. A trial date has been set for Feb. 24, 2020.

The firm saw growth of 8 percent in its life science business, 9 percent in its crosslabs group, and 9 percent in its diagnostics and genomics division in Q4.